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Abstract 
 
Introduction: Basal cell carcinoma (BCC) is the most frequent cancer with increasing 
incidence over the last decades. Standard of care is surgical excision, upon which  complete 
tumor clearance achieved in most cases. However, a small subgroup of patients will have 
remanence of disease post-excision and require further treatment options.. Over 90% of all 
BCCs carry a mutation in PTCH 1 or SMO, two conducting proteins of the Hedgehog 
pathway (Hh). Therefore, inhibition of the hedgehog pathway is a promising option for 
systemic first-line therapy. Vismodegib was the first developed of these small molecules, 
which was approved by the FDA in January 2012. Areas covered: The authors review current 
treatment modalities for basal cell carcinoma and discuss current developments in 
pharmacological therapy. The current literature including meta-analyses, the Cochrane 
database and registered as well as completed randomized controlled trials on 
www.ClinicalTrials.gov.  
 
Expert opinion: Hedgehog inhibitors are a new promising treatment option for patients with 
advanced or metastatic BCC. Phase I and II clinical trials withthe Hedgehog inhibitor, 
Vismodegib, showed  a significant reduction in in tumor size and appearance of new tumors 
with relative good tolerability.. Nevertheless, further investigation on new molecules and the 
effectiveness of an intermitting dosing-regimen is necessary. 
 
 
 
 
 
 
5 
 
 
1. Epidemiology 
 
Basal cell carcinoma (BCC) is the most frequently diagnosed skin cancer and most common 
cancer in humans of European ancestry with increasing rates of incidence 1. It comprises 
approximately 70% of all cutaneous cancers in Europe. Reliable data of the précis incidence 
are rare due to unsystematic documentation of diagnoses. However, the cancer registery for 
West-Switzerland has clearly documented an ongoing increase in incidence in males from 70 / 
100’000 per year in 1980’s to 140 / 100’000 per year in 1990’s with continuing trend. 
According to these data, estimated lifetime risk for BCC development in the collective of 
newborn children in Switzerland in the year 2000 is at least 1:10 2. BCC causes considerable 
morbidity and is one of the most expensive cancers to the health care managing systems 3. 
 
2. Aetiological risk factors and Pathobiology 
 
The overall lifetime risk for BCCs is estimated to be approximately 30%. The risk of 
development increases with age reaching its peak during 6th – 8th decades. The incidence is 
higher in males than in females. The history of at least one BCC bears a cumulative risk of 
more than 40% for developing further BCCs within the next 3 years. This suggests genetic 
alterations - besides pre-existence of other risk factors 4. 
The most important exogenous risk factor is exposure to ultraviolet (UV) radiation. Genotoxic 
damages induced by UV-B radiation (290 – 315 nm wavelength) 5-7 is  linked to the history of 
multiple sun burns in early ages and intensive intermittent sunlight exposure 8, 9.  The 
incidence of BCC is non-linearly correlated to the total UV exposure with peak at 
approximately two fold at 10,000–35,000 hours total sun exposure and remaining stable rates 
with additional exposure 10, 11. 
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Accordingly, lifestyle-related usage of indoor tanning and sun seeking behaviour might 
explain data showing increased incidence rates of BCC in younger population and women 12. 
Further risk factors are frequent x-ray irradiation 13, 14 and arsenic exposure 15 with known 
mutagenic effects on genes such as  p53. Additionally, the combination of arsenic and UV 
radiation enhances UV induced genotoxic damages by arsenic and its metabolite16-19. 
Iatrogenic immunosuppression - particularly in organ transplant recipients - is another risk 
factor for BCC development depending on duration and dosage of immunosuppressants 20. In 
immunocompromised population either caused iatrogenic or diseases such as AIDS, 
lymphoma or leukaemia BCC occur more often, in multiple numbers, aggressive forms and 
unusual locations 21-23. 
One of the most important genetic risk factor is fair skinned type I-II 24,which is based on the 
presence of melanin subtypes phaeomelanin (red-yellow pigment) and eumelanin (brown-
black pigment) that have protective role against UV radiation. In patients with albinism there 
the lack of melanin production due to mutation in the TYR gen, which results in increased 
photosensitivity and enhanced risk for developing BCCs, SCCs and melanoma 25. In case of 
variations of the melanocortin 1 receptor gene /MC1) that encodes the receptor for α-
melanocyte-stimulating hormone (αMSH), which is responsible for the switch between 
eumelanin and phaeomelanin and determining the intensity of skin pigmentation  26, the risk 
for developing BCC is increased 27, 28.  
Mutations of tumour suppressor genes such as p53 and  patched homologue 1 (PTCH1) are 
observed in more than 90% of BCCs and have been proven to be essential for its pathogenesis 
28-30.  BCCs are common early in life in patients with hereditary syndromes such as the 
Gorlin-Goltz-syndrome 31, Xeroderma pigmentosum 32, 33 24, Rombo-syndrome 34 or Bazex-
Dupré-Christol-syndrome 35. Patients who are affected by those syndromes, present BCCs 
already in early childhood 36-38. Sunscreens use by patients with history of BCC, showed that 
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the number of p53 mutations in tumours decreases upon UV protection underscoring the 
importance of consequent UV protection, especially in these patients 39. 
Most of basal cell carcinomas occur sporadically. Hereditary autosomal dominant Basal-cell 
nevus syndrome (Gorlin-Goltz syndrome or nevoid basal-cell carcinoma syndrome) is 
characterized by prominent susceptibility to develop multiple (up to hundreds) BCCs 40 and 
higher risk to develop other malignancies, especially medulloblastomas. Results of molecular 
genetic analysis revealed mutations in patched homologue 1 (PTCH1) gene located on 
chromosome 9q22 41-44. PTCH1 inhibits hedgehog (Hh) signalling pathway. Inactivating 
mutations in PTCH1 lead through loss of inhibition to pathway up-regulation and 
development of BCC 45, 46. 
 
2.1. Hedgehog Pathway 
 
Hedgehog (Hh) signalling pathway is a driving force of carcinogenesis with mutations found 
in more than 70% of sporadic BCC 47, 48, and 20-30% of medulloblastoma 49, 50. 
The Hh pathway was initially discovered in Drosophila melanogaster 51. This pathway is 
important for the embryonic development and differentiation of the cells. 
In adults, the Hh pathway is turned off in normal cells, except the cells hair, skin and stem 
cells 52. 
Hh signalling pathway entitled after the family of extracellular Hh ligands, includes several 
molecules that have ability mutually control their activity. The Hh family of protein ligands 
consists of three members: Sonic Hedgehog (SHh), Desert Hedgehog (DHh) and Indian 
Hedgehog (IHh) with capability to bind to PTCH (Figure 1). PTCH1, a 12-pass 
transmembrane receptor protein, has inhibitory action by binding to G protein-coupled 
receptor-like protein Smoothened (Smo), which serves as an pathway activator. Investigation 
in  medulloblastoma demonstrated that in the absence of SHh ligand, PTCH inhibits Smo 
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from being activated into SmoC, which leads to activation of transcription factor GLI 1/2/3 
through a series of protein interactions. Gli 1/2/3 regulate many genes that are active in stem 
cells.  
Khavari et al. reviewed experimental mouse models and clearly indicated that basal cell 
carcinoma in contrast to squamous cell carcinoma of the skin and cutaneous melanoma 
undergoes far less genetic alterations. Certainly it is important to target multiple pathways if 
they are clear drivers of the malignancies.  
SHh-overexpressing cells lead to expression of BMP-2B and bcl-2 - both Hh targets. 
Regenerated in immunodeficient mice, the histologic features of BCCs were shaped in the 
skin as well as the gene expression abnormalities of BCCs as decreased BP180/BPAG2 and 
laminin 5 adhesion proteins as well as expression of basal epidermal keratins were found 53, 54 
 
Besides PTCH, suppressor of fused (SUFU) was verified as negative regulator of Hh pathway 
by inhibiting Gli1 and Gli2 from entering the nucleus and converting Gli into its repressor 
form (GliR) with consecutive function as transcriptional repressor on the Gli target genes. 
In contrast, activated Gli (GliA) is associated with changes in transcription which leads to cell 
proliferation and differentiation55, 56. In addition, Smo accumulation relieves the suppression 
exerted by SUFU on the Gli transcription factors. Accordingly, inactivation of inhibitors 
PTCH1 or SUFU, caused by either mutation or otherwise degradation, as well as activation of 
Smo lead to Hh pathway activation 57.  
 
3. Clinical and histological aspects of BCCs 
The cell of origin in BCCs with its importance for pathogenesis and further development of 
targeted therapies is still not identified. Xenograft models showed that BCCs arise from 
keratinocytes in the epidermis. However, in these publications demonstrated assumptions 
differ between its origin in hair follicular bulge stem cells or long-term resident progenitor 
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cells of the interfollicular epidermis and upper infundibulum, in basal cell compartments of 
the epidermis, growing hair follicle or sebaceous glands depending on model and conceivably 
on histological subtype of BCC 58-61. 
BCCs are a heterogeneous group of tumors with varying clinical presentations and 
histological morphologies.  
Nodular BCC (nBCC) is the most common BCC, occuring most frequently on sun exposed 
areas in head and neck region and typically presents as an elevated reddish nodule with a 
shiny, translucent, tensed surface and teleangiectasias. The typical pearl-chain-like 
appearance at the edges, ulceration, cystic differentiation or pigmentation may also be found. 
The histopathological evaluation reveals basophilic lobules, columns or cords with peripheral 
palisading and cleft formation between tumor nests and the stroma as well as trichogen 
differentiation or sebaceous features. 
 
Superficial BCC (sBCC) presents clinically as erythematous patch with sharp demarcation 
and signs for erosions occurring in all body areas, especially in notsun-exposed areas such as 
the trunk. Their size may vary between a few millimeters up to many centimetres in diameter. 
Superficial lobules of basaloid cells confined to the papillary dermis, subepidermal tumor cell 
nests, accompanied by a pronounced stroma reaction with few inflammatory cells are seen on 
histopathology. Mixed patterns with nodular or an infiltrative component are rare but may 
occur. 
 
Morphoeic BCC presents as an infiltrated plaque, - flat or even sunken – lesion with poorly 
defined margins. Histologically, strands and nests of tumor cells are diffusely infiltrating, 
sometimes perineurally infiltrated and associated with a dense fibrous stroma reaction. 
Margins are often clinicallyunderestimated. 
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Less frequent subtypes are micronodular BCC, trichogen differentiated BCC, fibroepithelial 
BCC (Pinkus tumor) or Basosquamous carcinoma. 
 
Metastasis 
BCC with metastases are rare and controversely discussed. Recent retrospective analyses of 
the medical literature identified 172 cases published between 1981 and 2011. The median 
survival after the diagnosis was 54 months. As expected, the survival time is shorter for 
distant metastases (24 months) compared to local regional metastasizing BCCs (87 months). 
 
4. Current therapy of BCC 
 
4.1. Surgery, radiation, cryosurgery, photodynamic therapy 
 
Surgical excision with intra- or postoperative examination of the excised tissue to 
histologically confirm the clinical diagnosis is the gold standard of therapy. 
Only a small percentage of BCCs are unresectable or excision could lead to unacceptable 
functional and cosmetic defects. The unresectable  BCCs are considered to be locally 
advanced and may even be associated with metastases. Repeated surgical excisions can be 
problematic especially for  those with genetic disorders and the predilection for multiple 
BCCs during their lifetime such as seen in Gorlin-Goltz-syndrome. Prior to the development 
of new targeted therapy, treatment options for locally advanced BCCs and metastatic BCCs 
were very poor.  
The decision between conventional surgery with predetermined safety margins or a stepwise 
excision with correlated microscopical examination of peripheral and deep surgical tissue 
margins dependson  patient’s risk factors such as tumor size and site, definition of clinical 
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margins, histological subtype and features of aggression, failure of previous treatment and 
immunosuppression.  
In primary BCCs, conventional surgery with a safety margin according to subtype and size of 
the tumor is highly effective.  The recommended safety margin is 3-5mm in small, well 
defined lesions and wider excisions are recommended in morphoeic and largeer BCCs. 
Micrographic approach by Mohs or slow-Mohs (histographically controlled tumor margins on 
paraffin sections) surgery  are indicated for aggressive subtypes such as morphoeic, 
basosquamous, miconodular or infiltrative BCCs, recurrent or extended ( >2cm) tumors as 
well as difficult facial localizations with little skin reserves, perineural or perivascular 
involvement and poor clinical definitions of tumor margin 62-65. 
 
In case of multiple BCCs -or when surgery is impractical-  
other alternatives can be considered . Cryotherapy can be taken into account in presence of 
low risk solitary or multiple BCC with small and superficial lesions, especially in older 
patients or periocular localization. Disadvantages might be lower cure rate and sub-optimal 
cosmetic results caused by hypopigmented scares compared to surgical excisions 66. 
 
Moreover, Photodynamic therapy (PDT) is recommended for the treatment of sBCC and 
nBCC with a tumor thickness of 2 mm . This technique requires the simultaneous presence of 
a photosensitizer such as topical Aminolevulid-acid (ALA) or Methyl- ester derivate (MAL) - 
which can enhance penetration and have a higher tumor selectivity, – combined with an 
activating light and molecular oxygen 67. 
 
In a sBCC prospective randomized multicenter trial, photodynamic therapy (MAL-PDT) 
demonstrated  a better cosmetic outcome with similar high efficacy compared to surgery 68. 
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Radiotherapy using superficial x-rays or electrons is a suitable alternative especially in 
patients of advanced age (>60 years), anatomically critical localizations such as the periorbital 
region or or when surgery is contraindicated. .2 Nethertheless, radiotherapy is not suitable for 
morphoeic or desmoplastic BCC due to the  high risk of recurrence 65. 
 
4.2. Chemotherapy 
 
5-Fluorouracil (5-FU) 
5-FU is a pyrimidine analogue that inhibits the enzyme thymidylate synthase and thereby 
prevents DNA synthesis in tumor cells. In multiple superficial low risk, extrafacial BCCs or 
in patients with Basalcell naevus syndrome, topical 5-FU treatment  can be contemplated.  
Limited indications for treatment with 5-FU are based on studies showing that despite clinical 
appearance of tumor control achieved by superficial inhibition of growth, deeper tumor  parts 
are not treated sufficiently and  might continue to expandAdditional to DNA synthesis 
inhibition, 5-FU shows effects and interaction on Hedgehog pathway. In vitro investigations 
in human hepatocellular carcinoma cell lines suggested that 5-FU can down-regulate target 
molecules of the Hh Pathway at both mRNA and protein levels. Concerning effectiveness of 
combination 5-FU with smo inhibitor, cyclopamine, , mouse models in pancreatic tumours 
showed significantly higher tumour volume in mice injected with cyclopamine and 5-FU than 
in those injected with 5-FU alone. Concluded that Smo inhibitors may increase 
chemoresistance in some chemotherapy drugs like shown in hypoxic pancreatic cells 69. 
4.3. Imiquimod 
Application of topical imiquimod 5%is recommended in  multiple sBCC, low risk BCCs and 
extrafacial localizations,. Imiquimod is an imidazoquinolon causing inflammation with IFN-α 
driven immune response, inducing T cell mediated immunity and pro apoptotic effects. It 
directly activates innate immunity effectors such as plasmacytoid dendritic cells (PDCs) by 
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triggering toll-like receptor 7/MyD88/NF-κB pathway, leading to induction, synthesis and 
release of various cytokines, in particular IFN. Correlation between expression levels of IFN-
α-inducible genes and PDC counts, as well as tumor regression was shown 70. Additionally, 
imiquimod exerts pro-apoptotic activity against tumour cells with verified decrease of Bcl-2 
expression 71 and tumor suppressor function by induction of Notch signaling pathway whose 
activity is known to be decreased in BCCs by up-regulating protein expression of the Notch 
ligand, Jagged1 resulting together with its pro-inflammatory properties in tumor regression. 
Topical imiquimod 5% has been consistently superior to placebo in the treatment of 
immunocompetent patients with superficial BCCs in randomized, double-blinded trials. 
Complete clinical and histologically-verified clearance of the tumors occurred in 79–87% of 
imiquimod-treated patients after five-times-weekly or daily administration for 6-12 weeks. 
Similarly designed trials involving nodular BCCs were also performed, showing slightly 
lower histologically confirmed clearance of the treated tumors in 70-76% cases 72, 73. 
The 5 year follow up study showed clinical clearance rate of 89,6%, 12 weeks post-treatment 
and clinical clearance and histological clearance of 77.9% and 80.9%, respectively, at the end 
of follow-up after 5 years 74. 
 
4.4. Targeted therapies on Hh Pathway 
 
4.4.1. Cyclopamine 
 
The first well studied targeted therapy of the Hh pathway, was cyclopamine, an endogenous 
steroidal plant alkaloid derived from corn lilies 75. Cyclopamine competitively inhibits Smo 
by binding directly to the transmembrane domain of the protein. This induces midline 
deformities in embryogenesis  76 and leads to growth inhibition in malignant cells 75, 77. 
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Already in 2004, there was a report on the topical use of this inhibitor in few BCC patients. 
All of them experienced clinical  improvement with histological tumour regression attributed 
to induction of apoptosis 78. 
Consequently, synthetic Cyclopamine derivates were developed to optimize the inhibitory 
effects on the Hh signaling and encouraged elaboration of small molecule antagonist of Smo 
were found (e.g. GDC-0449, LDE225). The most promising specific Hh inibitor was 
Vismodegib (GDC-0449, Genentech), for which could be shown to have efficacy in patients 
with medulloblastoma 51. 
 
4.4.2. Vismodegib 
 
Vismodegib (2-chloro-N-(4-chloro-3-(pyridin-2-yl)phenyl)-4-(methylsulfonyl)benzamide) 
has shown in vivo activity in preclinical models of medulloblastoma 79, colon and pancreatic 
tumours 80, 81. In phase I clinical trials, vismodegib was relatively well tolerated with 
pharmacodynamic evidence of hedgehog pathway inhibition including GLI I suppression. A 
dose of 150 mg established a  reasonable safety profile and stable serum levels (80).  
A bioavailability of 31.8% was shown after a single dose of 150mg vismodegib in a clinical 
trial with healthy young women (83). Vismogdegib has a hepatic clearance of 82% and renal 
clearance of 4% (84). 
 
Von Hoff et al. reported a clinical trial investigating the safety and pharmacokinetics of 
vismodegib and tumor response in advanced BCCs with different dose levels. 18 of total 33 
patients experienced an objective tumour response including two complete remissions. In 
general, the treatment was comparatively well tolerated. Most common side effects (grade 2-
4) include fatigue, hyponatremia muscle spasm and weight loss. Increasing the dose did not 
result in higher blood plasma concentrations. The level of GLI down-regulation did not 
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correlate with the pharmacokinetic level of vismodegib I individual patients (81). Based on 
this data, a pivotal phase II clinical trial was initiated in patients with metastatic or locally 
advanced BCCs. The data presented by Sekulic et al. (82), have been updated and presented at 
the European Society of Medical Oncology Meeting in Vienna 2012. The investigators 
observed a 33.3 % response rate for metastatic BCCs and a 47.6% response rate for locally 
advanced BCCs (Table 1). The median duration of response was 7.6 months for metastatic 
BCCs and 9.5 month for locally advanced BCCs. Progression-free-survival was 9.5 months 
for both groups. Most frequent adverse effects included muscle spasm 71%, alopecia 65% and 
dysgeusia 53%, weight decrease 50% and fatigue 40% 82.  
Currently, a global single arm open label safety study with vismodegib in patients with 
advanced BCC (STEVIE study) is ongoing. The second interim analysis of this study was 
presented at the EADV meeting in Prague, September 2012. At this time point, already 150 
patients had a follow up of ≥ 3 months (138 patients with locally advanced and 12 with 
metastatic BCCs).. A preliminary best response was available for 124 patients. 19.4% 
experienced a complete response whether a partial responses were seen 55.6% of the patients 
83. Muscle spasms, alopecia, dysgeusia, asthenia and weight loss were the most common 
adverse effects. 
In September 2012, 423 patients have been recruited in 15 countries including Switzerland. 
The recruitment is ongoing. 
 
During the same time period, another phase II study with vismodegib was performed. I. 
Epstein and D. Bickers’ research groups investigated patients with Gorlin-Goltz syndrome 
(85). 41 patients were included in this randomized, double-blind, placebo-controlled trial. 
They were randomized 2:1 to receive vismodegib 150mg per day or placebo. Vismodegib 
therapy induced regressions of pre-existing BCCs and prevented the development of new 
BCCs in this patient population. At the planned second interim analysis in December 2010, 
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the data safety and monitoring board recommended ending the placebo treatment owing to 
statistically significant differences in efficacy favoring the vismodegib group. 
Vismodegib was approved under the trade name Erivedge® as the first Hedgehog pathway 
inhibitor, by the food and drug administration (FDA) in the US on January 30, 2012. 
 
4.4.3. Itraconazol 
 
The systemic antifungal drug itraconazol, an azol derivate that inhibits biosynthesis of 
ergosterol and cholesterol, was recently identified as an antagonist of Hh signaling. In vitro 
and mouse models demonstrated that itraconazol shows Smo- antagonism by binding as 
inverse agonist, leading to inhibition of Hh signaling pathway and tumor regression in 
medulloblastoma and BCC.  
As a result, further azol antifungals from the imidazole and triazole type such as fluconazole 
were tested but had no effects on Hh signaling pathway. It was concluded that inhibition of 
the Hh pathway is not due to a general class effect of azole-derivates. Additionally, a lipid 
interfering effect in blocking Hh reception through presumed sequestration of itraconazol by 
LDL was detected 84. 
 
According to these data, an ongoing open-label exploratory phase II clinical trial of oral 
itraconazol for the treatment of basal cell carcinoma is currently performed. Recently 
published dataon 19 patients treated with oral itraconazol 200 mg/d for 1 month or 400 mg/d 
for a not specified duration, showed a  reduction of BCC tumor size with 23% reduction in 
clinical tumor area, 45 % reduction of tumor proliferation and 65% in Hedgehog pathway 
activity 65. 
Further and long term results for the clinical relevance in the treatment of BCCs longtime 
known antifungal will be needed. 
17 
 
 
4.4.4. LDE 225 
 
LDE225, N-(6-((2S,6R)-2,6-dimethylmorpholino)pyridin-3-yl)-2-methyl-40-
(trifluoromethoxy)biphenyl-3-carboxamide,is a potent and selective small-molecule inhibitor 
of SMO, which is structurally distinct from cyclopamine. 
 
LDE 225 was investigated in a dose escalation phase I clinical trial in patients with advanced 
solid tumors. Most patients included in this trial suffered from locally advanced or metastatic 
BCC or recurrent medulloblastoma. 103 patients were included, from which 73 received the 
drug once daily and 30 patients received it twice daily. Most common adverse effects 
included nausea dysgeusia, weight loss, muscle spasms and myalgia often associated with 
increase of the serum creatin kinase (CK levels). In addition, alopecia and dysgeusia have 
been observed. The dose limiting toxicity was grade 3 / 4 - serum CK elevation at a dosage of 
more than 800 mg once daily or > 250 mg twice daily. This dose limiting toxicities were 
observed 3 and 6 weeks after treatment initiating, respectively. 6 of 16 patients with BCC 
(37%) and in addition 3 of 9 patients with medulloblastoma (33%) achieved objective tumour 
responses. Based on these promising results (J. Rodon et al., paper submitted), a randomized 
double-blind phase II clinical trial was initiated comparing the efficacy and safety of two 
levels of LDE 225 in patients with locally advanced BCC and metastatic BCC 85. One 
experimental arm is dosing LDE 225 at a dosage of 200 mg daily; the other arm applies 800 
mg daily. The primary objective is the rate of objective responses after 6 months of treatment. 
 
Topical 
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LDE 225 was also investigated as topical treatment in a doubleblind randomized vehicle-
controlled trial in 8 patients with Gorlin-Goltz syndrome. 27 BCCs were treated twice daily 
with a 0.75% LDE 225 cream or vehicle for 4 weeks. The topical therapy was well tolerated. 
There was hardly any inflammation. 3 out of 13 with LDE 225 treated BCCs showed a 
complete remission and 9 a partial remission clinically. However, histological investigations 
still showed remaining tumour nests that presented with reduced proliferation as assessed 
immunohistochemical by using expression of ki67 86. 
 
4.4.5. LEQ 506 and other smoothened inhibitors 
 
The efficacy and tolerance of further substances such as PI-926, BMS-838923 (XL139), 
TAK-441, PF-04449913 and LEQ, are currently explored in phase I and II trials for patients 
with BCCs as well as in patients with medulloblastoma or other cancerse.g. 506 85. The results 
of these studies are currently not available. 
 
. An ongoing phase II study in pediatric patients from 3 to 21 year old patients with 
medulloblastoma are treated with vismodegib 87. Data on geriatric patients are limited so far. 
So far no phase III trials have been initiated for Hh inhibitors due to the fact of missing 
compareable treamtents.  
 
Highlight Box 
• Basal cell carcinomas (BCC) are the most frequent cancer in human beings and 
standard of care is the surgical excision. 
• Over 90% of all BCC have a mutation in PTCH 1 or SMO, two conducting proteins of 
the Hedgehog pathway. 
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• Hedgehog inhibitors are a new option for a systemic treatment for locally advanced or 
metastatic BCC. 
• Vismodegib was the first drug to be approved by the FDA. 
• The most side effects are mild and overall well tolerated.  
 
 
5. Side effects 
 
Von Hoff et al. reported no grad 5 adverse events and only one grade 4 event was seen 
(asymptomatic hyponatremia). Several grade 3 events have been reported: fatigue, 
hyponatremia, weight loss, dyspnea, muscle spasm, atrial fibrillation, aspiration, back pain, 
corneal abrasion, dehydration, keratitis, lymhopenia, pneumonia, urinary tract infection and 
prolonged QT interval for vismodegib 88. 
1 out of 33 patients decided to discontinue the treatment after 8 months because of ongoing 
grade 1 adverse events (abdominal pain, fatigue, weight loss, dysgeusia) and grade 2 anorexia. 
In the study of Sekulic et al., all 104 patients had at least one adverse event 89. 57% showed 
grade 1 and 2 events , which was consistent with those from the phase I study. Grade 3 and 4 
adverse events included muscle spasms, weight loss, fatigue and loss of appetite (Table 2). 
25% of the events were considered serious adverse events and 7 patients experienced grade 5 
events (including death from unknown cause, hypovolemic shock, myocardial infarction, 
meningeal disease and ischemic stroke). The relationship of these fatal events and 
Vismodegib are unknown as they showed no definite pattern and all patients had clinically 
significant risk factors or coexisting conditions at baseline. 
About half the patients had discontinued the study at a median treatment duration of 
approximately 10 months. 18% in the metastatic BCC group because of disease progression 
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and in the other cohort 25% of the patients decided to stop the treatment on their own with to 
us unknown reasons. 
 
Tang et al. observed mild or moderate adverse events and no grade 5 events 90. Patients 
receiving Vismodegib had significantly more adverse events than patients on placebo. 
 
Also in this study patients have withdrawn their consent due to adverse events. The ceased 
shortly after ending with vismodegib: dysgeusia and muscle cramps within 1 month and the 
regrowth of hair were observed within 3 months. 
The adverse events of vismodegib are similar in all clinical trials done so far. The assumption 
is that they are mechanism-related.  
Hair follicle growth is initiated by the WNT signaling that induces the formation of the 
dermal condensate 91. For further development of the hair the Hedgehog pathway is required. 
Chiang et al. could show in their experiments with mice that hair germs consist of epidermal 
placodes and associated dermal condensates and are found in both, the control and the Shh -/- 
embryos. For the progression in the further development of the hair follicle the Sonic 
Hedgehog is needed and therefore this process is blocked in mutant skin 92. 
Furthermore, these rudimental hair follicles are capable of a localized growth and 
differentiation, but unable to form a normal hair 93.  
Similar to the process in the development of the hair, the Hh pathway also required for growth 
and patterning of the lingual taste papillae. Investigations on mice performed by Hall et al. as 
well as Liu et al. demonstrated that disruption of the Hh signaling pathway during 
embryogenesis results in an irreversibly altered number and location of fungiform papillae on 
the anterior tongue. Once papillae are well formed, hedgehog pathway is needed for the 
maintenance of the interpapillae space and papillae-free regions on the tongue 94 95. 
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6. Resistance 
 
Despite the promising results vismodegib showed in the past few years, there is already 
evidence about resistance to vismodegib. Rudin et al. reported in 2009 the case of a 26-year-
old male patient with medulloblastoma, who developed resistance after 3 months of therapy 
despite response at the beginning. The reason for the resistance was a heterozygous G to C 
missense mutation in SMO at position 1697 and changed the codon 473 from Asp to His 
(D473H). That led to an ineffective binding of vismodegib 51 96.  
Further research on the mechanism of resistance was performed by Dijkgraaf et al. They 
could proof that a modified SMO with an exchange of the amino acid aspartic acid at position 
473 resulted in a less sensitive binding of vismodegib than wild-type SMO 97. In addition they 
determined that mutation in E518 of SMO leads to a complete resistance of SMO to 
vismodegib. The amplification of GLI2 downstream of SMO was another mechanism of 
resistance to vismodegib 97. 
Itraconazol, a systemic azole antifungal agent, was recently detected to inhibit SMO in the Hh 
signaling pathway, but with another mechanism than the one of cyclopamine and with a less 
significantly potency than the currently available Hh inhibitors 84. According to the resistance 
by amplification of GLI2 it is also supposable to block the GLI function to overcome 
resistance. One such substance in development is GANT61 98. The identification of second-
generation SMO antagonists that show efficacy in SMO-Wildtype as well as SMO-mutants 
may be another suitable way to overcome resistance 97. 
Another potential resistance mechanism is the up-regulation of the phosphoinoditide 3-kinase 
(PI3K) pathway. It was detected that in NVP-LDE225-resistant samples (a new potent and 
selective oral SMO inhibitor from a newly described structural class 99. IGF1R-PI3K target 
genes were much upregulated comparing to drug-sensitive samples 100. This implicates that 
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the PI3K pathway is involved in the resistance mechanism of the Hh pathway. Targeting the 
PI3K pathway may provide a suitable solution in the situation of Hh 
 resistance. First encouraging results have been shown by Engelman et al. 101.  
So far there are no proven salvage therapies available to overcome acquired Hedgehog 
resistance, but the above mentioned ways are all promising approaches to therapy and need 
further investigation. 
 
7. Conclusion 
 
A careful analysis of the molecular pathways has identified the Hedgehog signaling pathway 
to be a key player involved in the biology of basal cell carcinoma and other cancer cells. This 
pathway is active during embryogenesis and essential for the orientation of the nervous 
system and other important compounds of a multi-organ organism. In adults this pathway is 
physiologically turned off, except in the stem cells of hair follicles, where it is essential for 
the re-initiation of the hair cycle. Because the activation of this pathway is limited especially 
to hair follicle cells and to basal carcinoma cells, it is a valuable targetable pathway in cancer 
therapy, providing a new promising treatment option for patients with advanced BCC and 
metastatic BCC as well as other tumors depending on the hedgehog pathway including 
medulloblastoma. Consequently, smoothened(SMO) inhibitors have been developed by 
several companies and successfully introduced into the clinicsVismodegib was very recently 
registered by the FDA (USA) for the treatment of advanced or metastatic basal cell 
carcinoma. Other substances will follow in the near future. 
 
In general, these molecules are well tolerated by the patients. However, the results of a long 
term use showed considerable discomfort of quality of life caused by the sum of all the side 
effects (muscle pain, dysgeusia and probably related to dysgeusia weight loss). This peculiar 
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spectrum of adverse effects can be challenging to manage especially in the typical BCC 
patient population of advanced age and many co-morbidities. The clinical research 
community has to develop strategies to cope with these problems. Intermittent dosing might 
be one of the options besides the search for supportive measures. 
 
The clinical data, which are available today, show convincingly the potency of smoothened 
inhibitors. However, they have never been investigated in randomized clinical trials. It might 
make sense to compare them to chemotherapy in very advanced basal cell carcinomas and 
explore topical strategies in patients with multiple basal cell carcinomas, including patients 
with Gorlin-Goltz syndrome.  
 
Based on the recently reported promising response rates, smoothened inhibitors might also be 
valuable drugs for the neo-adjuvant use in conjunction with surgery. In addition they might 
increase the radio sensitivity of basal cell carcinomas. These clinical questions have to be 
addressed in clinical trials in the near future.  
 
Furthermore, the studies in patients with Gorlin-Goltz syndrome indicate, that the systemic 
treatment with smoothened inhibitors can also prevent the development of new basal cell 
carcinomas in a high-risk patient population. Based on the fact that there is a substantial 
number of patients, who continuously develop new basal cell carcinomas, smoothened 
inhibitors hold promise for the chemoprevention of this very common skin carcinoma.  
 
In patients with a low tumor burden, the topical use of smoothened inhibitors should be 
explored in more detail. Early results have indicated some efficacy for this treatment, however 
there is no information on the histological clearing of the tumor cells and the optimal time and 
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dosing of topically used smoothened inhibitors. This approach would definitely avoid the 
significant side effects, especially after long term treatment of this drug class.  
In our opinion, smoothened inhibitors are essential in the repertoire of small molecules 
inhibitors. The importance of the Hedgehog signaling pathway in other malignancies is under 
investigation. 
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Figure 1: Hedgehog pathway in basal cell carcinoma cells. 
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Table 1: Updated response rates by independent reviewers of the ERIVANCE BCC study for 
patients under treatment with vismodegib 150mg per day. For patients with locally advanced 
 
 
 
mBCC ( n=33) 
 
laBCC ( n=63) 
 
26 November 
2010 
 
28 November 
2011 
 
26 November 
2010 
 
28 November 
2011 
 
OR, n (%)  
 
( 95% CI ) 
 
10 (30.3) 
 
(15.6 - 48.2) 
 
11 ( 33.3) 
 
(19.2-51.8) 
 
27 ( 42.9) 
 
(30.5-56.0) 
 
30 ( 47.6) 
 
(35.5- 60.6) 
 
Complete response, n 
 
 
0 
 
0 
 
13 
 
14 
 
Partial response, n  
 
 
10 
 
11 
 
14 
 
16 
 
Stable disease, n 
 
 
21 
 
20 
 
24 
  
22 
 
Progressive disease, n 
 
1 
 
1 
 
8 
 
8 
 
Missing or NEv  
 
 
1 
 
1 
 
4 
 
3 
 
Median DOR, months                          
( 95%CI) 
 
7.6 
(5.6- NE) 
 
7.6 
( 5.5- 9.4) 
 
7.6 
( 5.7- 9.7) 
 
9.5 
( 7.4- 21.4) 
 
Median PFS, months                 
(95%CI) 
 
9.5 
( 7.4- NE) 
 
9.5  
( 7.4- 11.1) 
 
9.5 
( 7.4- 11.9) 
 
9.5 
( 7.4- 14.8) 
BCC= basal cell carcinoma; CI= confidence interval; DOR= duration of response; laBCC= locally 
advanced BCC; mBCC= metastatic BCC; NA= not available; NE= not estimated; NEv= not 
evaluable; ORR= objective response rate;  PFS progression- free survival 
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BCC an overall response rate of 47.6% was seen. For metastatic basal cell carcinoma the 
ORR was 33.3% 82. 
 
 
 
 
 
Event Any 
Grade 
Grade 1 Grade 
2 
Grade 3 or 
4 
     
In percentage of 
patients 
    
     
Muscle spasms 68 48 16 4 
Alopecia 63 49 14 0 
Dysgeusia 51 28 23 0 
Decrease in weight 46 27 14 5 
Fatigue 36 27 5 4 
Nausea 29 21 7 1 
Decrease in appetite 23 14 6 3 
Diarrhea 22 16 5 1 
 
Table 2: Reported adverse events in the Erivance BCC study under treatment with vismodegib 
150mg per day 89. 
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